AKESO(HK:09926) Jin Rong Jie·2025-12-11 03:04Group 1 - The core point of the news is that Kangfang Biopharma's stock rose over 3% following the announcement of promising clinical trial results for its PD-1/VEGF bispecific antibody, Ivosidenib, in treating locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) [1] - Ivosidenib has shown significant clinical potential in first-line treatment for TNBC, as evidenced by updated efficacy data presented at the ESMO IO conference [1] - The drug has been included in the Breakthrough Therapy Designation (BTD) list by the National Medical Products Administration (NMPA) in China, indicating its promising efficacy and safety [1] Group 2 - Ivosidenib is the world's first PD-1/VEGF bispecific antibody developed by Kangfang Biopharma, with its first indication expected to receive approval from the NMPA in May 2024 for treating locally advanced or metastatic non-small cell lung cancer (nsq-NSCLC) [2] - The drug represents a novel combination of tumor immunotherapy and anti-angiogenesis mechanisms, marking a significant advancement in cancer treatment [2] - In November 2024, Ivosidenib was included in the national medical insurance catalog, enhancing its accessibility for patients [2]